The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.

In previously untreated RAS wild-type metastatic colorectal cancer, adding either cetuximab or panitumumab to chemotherapy produced benefits for patients, but neither was likely to be good value for money for the NHS at list prices.

http://ift.tt/2uOHkHZ